Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2005 by Laboratoires Arkopharma.
Recruitment status was  Active, not recruiting
Information provided by:
Laboratoires Arkopharma Identifier:
First received: October 7, 2005
Last updated: December 7, 2005
Last verified: October 2005

October 7, 2005
December 7, 2005
June 2004
Not Provided
- Endometrial innocuity (endometrial biopsy result)
Same as current
Complete list of historical versions of study NCT00235924 on Archive Site
  • - Mammary innocuity (mammography results)
  • - climacteric symptoms
  • -Lipid profile
  • -gynaecological and general safety
Same as current
Not Provided
Not Provided
Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women
Study Assessing the Effects on Endometrium and Breast of a Standardized Isoflavone Extract(Phytosoya) in Post Menopausal Women.

The main objective of this study is to determine the effects on the endometrium and breast of 70 mg daily dose of isoflavones.

This is an international multicentre open study, assessing the innocuity on breast and endometrium of a 70 mg daily dose of isoflavones standardized extract (Phytosoya).

This study follows the European guidelines :one-year treatment duration, biopsy and mammography performed at the beginning and at the end of the trial, recruitment of enough subjects in order to have 300 patients with an evaluable biopsy after one year of treatment.

After 3 weeks of screening phase, the patients will be taken Phytosoya during 52 weeks. At the end of the first year of treatment, an endometrial biopsy, an endovaginal ultrasonography, a mammography, breast ultrasounds, a clinical examination and a biological assessment will be performed.

In addition, it will be proposed to patients to continue treatment during 2 additional years. At the end of the third year,the same examinations will be performed.

Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Drug: soy isoflavone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
Not Provided

Inclusion Criteria:

  • Not hysterectomised women
  • Post menopausal (at least 2 years)
  • FSH superior to 30 UI/l and oestradiol inferior to 35 ng/ml
  • Presenting with hot flushes (but not incapacitating) or climacteric symptoms

Exclusion Criteria:

  • History of endometrial hyperplasia
  • Known hormono-dependent malignant tumours
  • BMI superior to 30 Kg/m2
  • Uncontrolled arterial hypertension
  • Known renal or liver insufficiency
  • Recent or evolutive thromboembolic disease
  • Unexplained bleeding, endometrial polyps, submucous myomas, active endometriosis, ovarian cyst superior to 30 mm
  • Local hormonal treatment, raloxifene,tibolone within the 3 months before V1 and during the study
  • HRT and DHEA within the 3 months before V2 and during the study
  • isoflavones within the 2 months before V2 and during the study
  • clonidine, beta-alanine, veralipride within 1 month before V1 and during the study.
45 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Laboratoires Arkopharma
Not Provided
Study Chair: Pierre MARES, Professor Hospital of Caremeau, Nîmes, FRANCE
Principal Investigator: Santiago PALACIOS, Professor Instituto Palacios, Madrid, SPAIN
Principal Investigator: Bruno PORNEL, Doctor Brussels Menopause Center, Bruxelles, BELGIUM
Principal Investigator: John EDEN, Professor Sydney Menopause Center, Sydney, AUSTRALIA
Laboratoires Arkopharma
October 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP